Merus (NASDAQ:MRUS) Holdings Raised by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC raised its stake in shares of Merus (NASDAQ:MRUS - Free Report) by 21.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 331,195 shares of the biotechnology company's stock after buying an additional 58,760 shares during the period. TimesSquare Capital Management LLC owned about 0.48% of Merus worth $13,927,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Avior Wealth Management LLC bought a new position in Merus in the 4th quarter worth $76,000. US Bancorp DE bought a new position in Merus in the 3rd quarter worth $103,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Merus by 24.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company's stock worth $118,000 after buying an additional 489 shares during the period. MML Investors Services LLC bought a new position in Merus in the 3rd quarter worth $206,000. Finally, Gordian Capital Singapore Pte Ltd boosted its holdings in Merus by 10.4% in the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company's stock worth $250,000 after buying an additional 470 shares during the period. 96.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MRUS. UBS Group began coverage on shares of Merus in a research report on Thursday, October 24th. They set a "buy" rating and a $72.00 target price on the stock. Piper Sandler began coverage on shares of Merus in a research report on Thursday, February 13th. They set an "overweight" rating and a $84.00 target price on the stock. Guggenheim restated a "buy" rating on shares of Merus in a research report on Wednesday, February 12th. Needham & Company LLC reissued a "buy" rating and issued a $85.00 price objective on shares of Merus in a research report on Monday, December 9th. Finally, Wells Fargo & Company started coverage on shares of Merus in a research report on Friday, February 7th. They issued an "overweight" rating and a $91.00 price objective on the stock. One analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Merus has a consensus rating of "Buy" and a consensus target price of $85.92.

Merus Price Performance

Shares of MRUS stock traded down $0.22 during trading hours on Friday, reaching $47.41. 414,215 shares of the stock were exchanged, compared to its average volume of 596,508. The business's fifty day moving average is $41.63 and its two-hundred day moving average is $46.97. Merus has a 12-month low of $37.77 and a 12-month high of $61.61. The firm has a market capitalization of $3.25 billion, a P/E ratio of -12.01 and a beta of 1.11.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.